tradingkey.logo

Amarin Corporation PLC

AMRN
查看詳細走勢圖
14.750USD
+0.660+4.68%
收盤 02/06, 16:00美東報價延遲15分鐘
306.77M總市值
虧損本益比TTM

Amarin Corporation PLC

14.750
+0.660+4.68%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.68%

5天

-1.14%

1月

+5.13%

6月

-2.32%

今年開始到現在

+5.70%

1年

+36.32%

查看詳細走勢圖

TradingKey Amarin Corporation PLC股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Amarin Corporation PLC當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名112/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為12.00。中期看,股價處於平穩狀態。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Amarin Corporation PLC評分

相關信息

行業排名
112 / 392
全市場排名
243 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

Amarin Corporation PLC亮點

亮點風險
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
估值高估
公司最新PE估值-3.53,處於3年歷史高位
機構加倉
最新機構持股4.18M股,環比增加0.10%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉0.00股

分析師目標

基於 2 分析師
持有
評級
12.000
目標均價
-17.81%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Amarin Corporation PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Amarin Corporation PLC簡介

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
公司代碼AMRN
公司Amarin Corporation PLC
CEOBerg (Aaron D)
網址https://amarincorp.com/
KeyAI